Trial Profile

Phase 3 trial of ABP-671 in chronic gout patients with mild to moderate renal impairment

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lingdolinurad (Primary)
Indications Gout
Focus Therapeutic Use

Most Recent Events

18 Nov 2025 New trial record
21 Oct 2025 According to an Atom therapeutics media release, based on results from phase 2a Study (NCT04638543), company will enroll chronic gout patients with mild to moderate renal impairment in future Phase 3 trials of ABP-671.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com